1.The report on baseline survey for use of mercury-based medical devices in health care organizations of Mongolia
Ichinkhorloo B ; Ulziisaikhan S ; Tsengelmaa M ; Enkhtsetseg SH ; Unursaikhan S
Mongolian Medical Sciences 2010;153(3):72-77
Goal: To conduct mercury-based medical devises used in health care organizations and develop strategy and recommendations on futher activityMaterial and Methods:A cross-sectional study design was used. Totally 578 units of 38 governmental and private health care organizations inUlaanbaatar, Darkhan, Erdenet cities and Uvurkhangai aimags were conducted in the survey. The survey was conductedby means of a questionnaire given to the medical workers and doctors to complete. There were 3 parts of questions. Thefirst part of the questionnaire dealth with the use of mercury-based medical devices, working, transportation and storageconditions, and waste management. The second section was concerned with knowledge, attitude and practice (KAP) ofmedical personals for safety handling, storage and disposal of mercury containing devices. The third part of the questionnairedealth with the dental amalgam.Mercury concentration of dental amalgam samples were detected by portable mercury vapor analyser RP-91, PYRO-915+ in the Poison Information Center of Public Health Institute. Data processing was done by using statistical programSPSS-10.Conclusions:1. Mercury containing devices such as thermometer, blood pressure sphygmomanometer, energy saving fluorescencelamp and termostates were used in urban and rural hospitals. There are not any regulations for safe handling,storage, and transportation and disposal system of mercury containing divices.2. Knowledge on handling, storaging and disposing mercury based devices are not enough among the medical personals.The current situations for inapproiprate disposal system can be posed to increase riskes of environmentalpollution with mercury.3. Knowledge on health impact of spilled mercury from broken mercury based medical devices is not enoughamong the medical workers. Safety manual for handling, storage and disposal of mercury based medical devicesand promotion materials for health adverse effect and prevention methods have not been developed.4. 14.7% of the investigated dental hospitals and cabinets were used dental amalgam for treatment. Of these wasinvolved the fist stage hospitals. Dental amalgams were imported from China and Russia. Any special recommendationsand rules for safe use, storage and disposal of dental amalgam have not developed.
2.Outcomes of retinopathy of prematurity screening at National Center For Maternal And Child Health
Tsengelmaa Ch ; Erdenetuya G ; Tsogzolmaa G ; Gantuya M ; Amgalan P ; Enkhtuya S ; Altantuya Ts ; Bayalag M
Innovation 2021;14(1-Ophthalmology):22-25
Purpose:
To investigate the outcomes of ROP screening of retinopathy of prematurity (ROP).
Methods:
This was a prospective of prematurity infants screened ROP from 2020 April 13th to
April 28th 2020 and from 2020 June 08 th to June 22th 2020 and prospective cohort study of
premature infants with treatment-requiring ROP who received intravitreal injections, laser surgery.
Demographic factors, diagnosis and clinical course were recorded. Indirect ophthalmoscopy
and Retinal imaging was performed using RetCam (Natus Medical, Pleasanton, CA) and
images were taken. Each eye was evaluated by the pediatric ophthalmologist and aimag’s
ophthalmologist for the presence or absence of ROP, zone of vascularization, stage, plus disease,
and aggressive posterior ROP (AP-ROP). The diagnosis and classification of ROP for this current
study were determined by examination using indirect ophthalmoscopy, and treatment plans
were determined according to the International Classification for ROP and the Early Treatment for
ROP Study (ET-ROP).2,13
Results:
A total of 90 premature infants with BW ≤ 2000g and/or GA ≤ 34 weeks were screened for
ROP during the study period. 8 (8.8%) of the 90 infants screened required treatment. The 8 infants
who received ROP treatment had a mean GA of 28.5 ± 1.7 weeks, mean BW of 1237.5 ± 125.42g,
mean PMA of 36 weeks and mean follow-up time of 2 months.
Conclusion
After treatment, resolution of ROP was noted in approximately 100 % of the patients
who had treatment-requiring ROP.